Ultragenyx (RARE) Receives a Buy from Jefferies


In a report released yesterday, Maury Raycroft from Jefferies reiterated a Buy rating on Ultragenyx (NASDAQ: RARE), with a price target of $98. The company’s shares closed on Friday at $71.81.

According to TipRanks.com, Raycroft is a 4-star analyst with an average return of 25.5% and a 52.0% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $86.50 average price target, implying a 20.5% upside from current levels. In a report issued on July 25, Cowen & Co. also assigned a Buy rating to the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $87.33 and a one-year low of $41.67. Currently, Ultragenyx has an average volume of 540.9K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts